Citadel Advisors LLC Acquires New Stake in Oculis Holding AG (NASDAQ:OCS)

Citadel Advisors LLC purchased a new position in shares of Oculis Holding AG (NASDAQ:OCS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 22,911 shares of the company's stock, valued at approximately $389,000. Citadel Advisors LLC owned about 0.06% of Oculis as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the business. abrdn plc grew its stake in shares of Oculis by 23.0% during the fourth quarter. abrdn plc now owns 1,009,424 shares of the company's stock worth $17,150,000 after acquiring an additional 188,871 shares during the last quarter. Bank of America Corp DE boosted its position in Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after buying an additional 10,667 shares during the last quarter. Geode Capital Management LLC boosted its position in Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock valued at $284,000 after buying an additional 1,800 shares during the last quarter. XTX Topco Ltd purchased a new stake in Oculis in the fourth quarter valued at approximately $225,000. Finally, Bellevue Group AG purchased a new stake in Oculis in the fourth quarter valued at approximately $170,000. Hedge funds and other institutional investors own 22.30% of the company's stock.

Oculis Stock Performance

Oculis stock traded up $0.41 during mid-day trading on Thursday, hitting $19.56. The company had a trading volume of 34,216 shares, compared to its average volume of 44,194. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. Oculis Holding AG has a 12-month low of $10.79 and a 12-month high of $23.08. The company's fifty day moving average is $17.87 and its 200-day moving average is $18.64. The company has a market capitalization of $854.03 million, a price-to-earnings ratio of -10.13 and a beta of 0.27.

Oculis (NASDAQ:OCS - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). The business had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.22 million. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. Equities research analysts predict that Oculis Holding AG will post -2.09 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on OCS. HC Wainwright upped their target price on Oculis from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Thursday, April 17th. Robert W. Baird upped their target price on Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a research report on Thursday, March 13th. Finally, Chardan Capital upped their target price on Oculis from $28.00 to $33.00 and gave the company a "buy" rating in a research report on Friday, May 9th.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.